RXST
RxSight, Inc.12.76
+0.24+1.92%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Guidance granularity, margin details
Q&A drilled into 2026 guidance details absent from prepared remarks, assuming low single-digit LAL unit growth with utilization steady at 8 lenses per LDD monthly and LDD sales accelerating modestly from Q4's 25 units, setting up back-half recovery amid easier comps. Gross margins face transient H1 pressure from high-cost inventory flush, but high-70s remain feasible long-term on favorable mix. Early commercial pivot wins show promise, yet require sustained practice support beyond one-offs. Competition? Episodic launches, nothing structural. Management sounded prudently confident; watch utilization durability.
Key Stats
Market Cap
524.65MP/E (TTM)
-Basic EPS (TTM)
-0.88Dividend Yield
0%Recent Filings
8-K
2025 revenue down 4%
RxSight reported 2025 revenue of $134.5 million, down 4% from 2024 as LDD sales plunged 48%, though LAL units rose 12% to 109,615 and gross margin expanded to 76.6%. Q4 revenue fell 19% to $32.6 million, with net loss widening to $(9.2) million. LDD installed base hit 1,134. Guides 2026 revenue to $120–$135 million amid lower LDD placements.
10-K
FY2025 results
RxSight's FY2025 sales dipped 3.9% to $134.5M despite 12% LAL implant growth to 109,615 units, as LDD placements plunged 47% to 163 reflecting adoption slowdown—yet Q4 LALs rose to 28,611 from Q3's 26,045 amid realigned commercial teams. Gross margins expanded to 76.6% on LAL mix (80% revenue), but operating losses widened 31% to $48.2M from SG&A (+11%) and R&D (+12%) investments. Cash reserves stood at $228.1M with no debt, funding runway past 12 months. Q4 stabilized momentum, but securities litigation clouds near-term risks.
8-K
CFO appointed; Q4 revenue $32.6M
RxSight appointed Mark Wilterding as CFO effective January 11, 2026, replacing Shelley Thunen, with $550,000 base salary, 65% bonus target, and equity awards of 258,770 options plus 163,528 RSUs. Wilterding brings 25 years' experience from Edwards Lifesciences and Medtronic. New CFO starts now. Preliminary Q4 revenue hit $32.6M on 28,611 LALs sold; full-year $134.5M beat guidance.
8-K
CFO transition finalized
8-K
CFO Thunen transitioning out
RxSight's CFO Shelley Thunen announced her transition out, effective upon successor appointment or January 31, 2026, followed by consulting through December 31, 2026 at $500/hour plus $15,000 monthly retainers. She secures her 2025 bonus and salary through transition. Leadership change disrupts finance continuity.
ALC
Alcon Inc.
79.02-0.17
CVRX
CVRx, Inc.
8.32+0.14
GKOS
Glaukos Corporation
113.76+2.03
IRIX
IRIDEX Corporation
1.00+0.02
LNSR
LENSAR, Inc.
12.06+0.54
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
SGHT
Sight Sciences, Inc.
8.39+0.08
SRTS
Sensus Healthcare, Inc.
3.80+0.11
STAA
STAAR Surgical Company
24.80+1.24
VYCO
Vycor Medical, Inc.
0.16+0.00